Expert-Guided Large Language Models for Clinical Decision Support in Precision Oncology.


Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 30 10 2024
pubmed: 30 10 2024
entrez: 30 10 2024
Statut: ppublish

Résumé

Rapidly expanding medical literature challenges oncologists seeking targeted cancer therapies. General-purpose large language models (LLMs) lack domain-specific knowledge, limiting their clinical utility. This study introduces the LLM system Medical Evidence Retrieval and Data Integration for Tailored Healthcare (MEREDITH), designed to support treatment recommendations in precision oncology. Built on We evaluated MEREDITH on 10 publicly available fictional oncology cases with iterative feedback from a molecular tumor board (MTB) at a major German cancer center. Initially limited to MEREDITH identified a broader range of treatment options (median 4) compared with MTB experts (median 2). These options included therapies on the basis of preclinical data and combination treatments, expanding the treatment possibilities for consideration by the MTB. This broader approach was achieved by incorporating a curated medical data set that contextualized molecular targetability. Mirroring the approach MTB experts use to evaluate MTB cases improved the LLM's ability to generate relevant suggestions. This is supported by high concordance between LLM suggestions and expert recommendations (94.7% for the enhanced system) and a significant increase in semantic similarity from the draft to the enhanced system (from 0.71 to 0.76, Expert feedback and domain-specific data augment LLM performance. Future research should investigate responsible LLM integration into real-world clinical workflows.

Identifiants

pubmed: 39475661
doi: 10.1200/PO-24-00478
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400478

Auteurs

Jacqueline Lammert (J)

Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.
EUropean Network for RAre CANcers (EURACAN) Initiative, partner site Munich, Munich, Germany.

Tobias Dreyer (T)

Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.

Sonja Mathes (S)

Department of Dermatology and Allergy Biederstein, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Institute for History, Theory and Ethics of Medicine, University of Mainz Medical Center, Mainz, Germany.

Leonid Kuligin (L)

Google Cloud, Munich, Germany.

Kai J Borm (KJ)

Department of Radiation Oncology, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Bavarian Center for Cancer Research (BZKF), Technical University of Munich partner site, Munich, Germany.

Ulrich A Schatz (UA)

Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Marion Kiechle (M)

Department of Gynecology and Center for Hereditary Breast and Ovarian Cancer, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Alisa M Lörsch (AM)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Department of Medicine III, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Johannes Jung (J)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Department of Medicine III, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Sebastian Lange (S)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Department of Medicine II, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Nicole Pfarr (N)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Anna Durner (A)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Kristina Schwamborn (K)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Christof Winter (C)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.
Institute of Clinical Chemistry and Pathobiochemistry, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Dyke Ferber (D)

Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.
National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.

Jakob Nikolas Kather (JN)

Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.
National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Department of Medicine I, University Hospital Dresden, Dresden, Germany.

Carolin Mogler (C)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.
Institute of Pathology, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Anna L Illert (AL)

Center for Personalized Medicine (ZPM), Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and TUM University Hospital, Munich, Germany.
Bavarian Center for Cancer Research (BZKF), Technical University of Munich partner site, Munich, Germany.
Department of Medicine III, Technical University of Munich (TUM), School of Medicine and Health, Klinikum rechts der Isar, TUM University Hospital, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH